LESS IS MORE

Statin Use in Very Elderly Individuals, 1999-2012
There is little randomized evidence to guide the use of statins (HMG-CoA reductase inhibitors) in very elderly individuals (>79 years). 1, 2 Despite this, the very elderly have the highest rate of statin use in the United States. 3 Given that few studies have investigated the use of statins among this population in a longitudinal manner by vascular disease, we set out to do so.
Methods | The 1999-2012 Medical Expenditure Panel Survey (MEPS) was used for the analysis. 4 The MEPS is nationally representative of the civilian noninstitutionalized population of the United States for each year and is sponsored by the Agency of Healthcare Research and Quality and the Centers for Disease Control and Prevention. The survey consists of 5 interviews over 2 years and contains self-reported demographics, medical conditions, and prescription drug information. The analysis included all individuals older than 79 years without liver disease. Prescription drug information was verified by pharmacy data and has been shown to be valid and not biased by sociodemographic variables. 5 Statins were identified, and use was classified as the report of any statin prescription. Atorvastatin or rosuvastatin were considered highpotency statins. Primary prevention was defined as individuals without vascular disease (coronary heart disease [CHD], stroke, or peripheral vascular disease). Secondary prevention was defined as vascular disease, which increased in 2007 after questions regarding CHD and/or stroke were asked at every interview instead of once a year. Logistic regression was used to investigate trends in medication use, while multivariable logistic regression was used to determine if high-potency statin use was associated with vascular disease controlling for year. A sensitivity analysis was conducted that included individuals with diabetes mellitus in the secondary prevention group. Complex survey weighting was included in all analyses, using STATA statistical software (version 13; STATA Corp). The Ohio State University institutional review board ruled this study exempt from review. 
Rates of Kidney Transplantation From Living and Deceased Donors for Blacks and Whites in the United States, 1998 to 2011
Kidney transplantation, the treatment standard for patients with end-stage renal disease (ESRD), is associated with prolonged survival, improved quality of life, reduced morbidity, and lower health care costs compared with dialysis. 1 Racial disparities in kidney transplantation are well documented; studies show that black patients are less likely than white patients to be referred for transplant evaluation, registered for transplantation, progress through the waiting list, and ultimately receive a transplant. 2 The effects of ongoing efforts to eliminate these disparities are uncertain. 3 We used data from the United Network of Organ Sharing (UNOS) registry to examine current patterns of racial disparities in kidney transplantation. To focus on the decision to refer patients for transplantation, we used patients with ESRD as the denominator, not patients on the transplant waiting list.
Methods | To identify transplant recipients and living donors, we queried the UNOS data registry (1998 to 2011). We obtained data on the incidence of ESRD, stratified by race, from the United States Renal Data System and calculated temporal trends in kidney transplantation (per 1000 patients with ESRD) for all transplant recipients and separately for those with deceased and living donors. We adjusted the trends for age, sex, ESRD cause, and geographic region using the direct-iterative adjustment method 4 and reported the adjusted trends using the estimated annual percent change methodology.
Results | Between 1998 and 2011, 184 303 patients, 13.5% of the 1 355 671 patients with ESRD in the United States Renal Data System, underwent kidney transplantation. Of these patients, 37.1% (n = 68 381) underwent living donor transplantation. Figure 1 shows that the incidence of kidney transplantation in black patients increased at an annual rate of 2.84% from 93 per 1000 patients with ESRD in 1998 to 128 per 1000 in 2011 (95% CI, +2.32% to +3.41%; P < .001). Thus, by 2010, the incidence of kidney transplantation for black and white patients was equivalent. In whites, the rate of transplantation from deceased donors declined between 1998 and 2011 (estimated annual percent change, −1.66%; 95% CI, −2.11% to −1.20%; P < .001), while the rate of transplantation from living donors was unchanged (estimated annual percent change −1.05%; 95% CI, −2.33% to +0.24%; P = .14) (Figure 2A) . For black patients, the rate of kidney transplantation from deceased donors increased (estimated annual percent change, +3.49%; 95% CI, +2.81% to +4.29%; P < .001), while the rate of transplantation from living donors was unchanged (estimated annual percent change, +0.14%; 95% CI, −1.73% to +2.01%; P = .88) ( Figure 2B ). Over the study period, the percentages of kidney transplants from living donors were 43.2% for white patients and 22.2% for black patients. Of live kidney donations, 15.5% were from black donors; the rate remained stable (estimated annual percent change, −0.78%; 95% CI, −2.53% to +1.21%; P = .45).
